Obsessive Compulsive Disorder Clinical Trial
Official title:
Overlapping Neural Circuits Implicated in Pediatric OCD
Verified date | August 2023 |
Source | New York State Psychiatric Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to examine the brain functioning of children and adolescent with OCD before and after treatment with Exposure and Response Prevention (EXRP) therapy.
Status | Completed |
Enrollment | 55 |
Est. completion date | September 30, 2021 |
Est. primary completion date | September 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 5 Years to 17 Years |
Eligibility | Patient Inclusion Criteria: - Participants must be 5-17 at the time of consent - Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Diagnosis of OCD as the principal problem - Not on psychotropic medication and not receiving current psychotherapy for OCD - Written informed assent by the participants (8 and older) and consent by the parent - Participants and a parent/guardian must be able to read and understand English Patient Exclusion Criteria: - DSM-IV current diagnosis of major depressive disorder, attention-deficit hyperactivity disorder, Tourette's/Tic Disorder, or substance/alcohol abuse - DSM-IV lifetime diagnosis of psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder, or substance/alcohol abuse - Active suicidal ideation - Females who are pregnant or nursing - Major medical or neurological problems - Presence of metallic device or dental braces - IQ<80 - A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) - Individuals who are currently receiving CBT, other forms of psychotherapy, or psychotropic medications - Individuals who have received a full course of CBT in the past - A positive pregnancy test - Positive urine screen for illicit drugs - Inability of participant or parent/guardian to read or understand English Healthy Control Inclusion Criteria: - Participants must be 5-17 at the time of consent - Written informed assent by the participants (8 and older) and consent by the parent - Participants and a parent/guardian must be able to read and understand English Healthy Control Exclusion Criteria: - Any current or lifetime psychiatric diagnosis - Active suicidal ideation - Females who are pregnant or nursing - Major medical or neurological problems - Presence of metallic device or dental braces - IQ<80 - A current or past diagnosis of pediatric autoimmune neuropsychiatric disorders associated with streptococcus (PANDAS) - A positive pregnancy test - Positive urine screen for illicit drugs - Inability of participant or parent/guardian to read or understand English |
Country | Name | City | State |
---|---|---|---|
United States | NY State Psychiatric Institute | New York | New York |
Lead Sponsor | Collaborator |
---|---|
New York State Psychiatric Institute | National Institute of Mental Health (NIMH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Brain Activation Associated With the Resolution of Cognitive Conflict | Task-based functional magnetic resonance imaging (fMRI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs) during their performance of a Simon Spatial Compatibility Task.
In each trial, participants are presented with a leftward or rightward pointing arrow that is either congruent or incongruent with their position (left or right) on the screen. Participants are instructed to respond as quickly and accurately as possible to the direction in which the arrow was pointing by pressing a button on a response box using the index finger for left and the middle finger for right. Brain activation during the resolution of cognitive conflict is computed by contrasting blood-oxygen-level-dependent (BOLD) signal during Incongruent versus Congruent trials. BOLD signal is expressed in arbitrary units (A.U.s). |
single time point: baseline | |
Secondary | Functional Connectivity | Functional magnetic resonance imaging (fMRI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs) at baseline and after approximately 16-20 weeks (i.e., post-treatment for the participants with OCD). The whole brain is divided in 352 brain regions comprised of 333 cortical surface (Gordon et al. Cereb Cortex 2016;26:288-303) and 19 subcortical (Fischl et al. Neuron 2002;53:341-55) parcellated regions. FC-strength (average of Fisher-r-to-Z transformed Pearson correlation coefficients) between each region was computed.
Values >0 indicate regions are positively connected (synchronized), with larger values indicating stronger connection. Values <0 indicate regions are negatively connected (inversely synchronized), with more negative values stronger negative connection. A value of 0 indicates that the regions are not connected. |
single time point: Baseline | |
Secondary | Brain Gray Matter Thickness | Structural MRI will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs). Regional cortical thickness will be computed in the inferior frontal gyrus | Single time point: Baseline | |
Secondary | Structural Connectivity (Streamline Counts) | Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI) will be acquired from children and adolescents diagnosed with OCD and healthy comparison subjects (HCs). A structural connectivity matrix is estimated for each participant using the standard MRtrix3 preprocessing pipeline, yielding 164x164 symmetrical streamline count matrix for each participant using the FreeSurfer segmentations/parcellations noted above (148 cortical, 14 subcortical regions, and the left and right cerebellum). Using this approach, streamline count between brain regions is proportional to the cross-sectional area of white matter fibers connecting those regions. Thus, streamline count is a biologically plausible metric of "structural connectivity" proposed to represent the communication 'bandwidth' between regions. | Single time point (baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04631042 -
Developing Brain, Impulsivity and Compulsivity
|
||
Completed |
NCT02855580 -
Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
|
||
Completed |
NCT02202915 -
CBT for Pediatric OCD: Community Training Pilot
|
N/A | |
Completed |
NCT02229903 -
An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD
|
N/A | |
Completed |
NCT01794156 -
Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder
|
N/A | |
Completed |
NCT02089984 -
Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders
|
N/A | |
Completed |
NCT01348529 -
Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT00965211 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome
|
N/A | |
Completed |
NCT01172873 -
D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD
|
N/A | |
Not yet recruiting |
NCT00743834 -
Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)
|
Phase 4 | |
Completed |
NCT00723060 -
Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder
|
Phase 4 | |
Completed |
NCT01981317 -
Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder
|
N/A | |
Completed |
NCT02194075 -
Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder
|
Phase 4 | |
Completed |
NCT01686087 -
Attaining and Maintaining Wellness in Obsessive-compulsive Disorder
|
N/A | |
Terminated |
NCT00997087 -
A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder
|
Phase 2 | |
Completed |
NCT01331876 -
Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy
|
N/A | |
Completed |
NCT00533806 -
Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder
|
Phase 3 | |
Completed |
NCT00517244 -
Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders
|
N/A | |
Completed |
NCT00169377 -
Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)
|
Phase 1/Phase 2 | |
Completed |
NCT00116532 -
Escitalopram for the Treatment of Obsessive Compulsive Disorder (OCD)
|
Phase 4 |